NSCLC

[HUTCHMED, Ltd.] HUTCHMED Limited and AstraZeneca PLChave initiated SANOVO, a China Phase III study of ORPATHYS®, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (EGFR) TKI, TAGRISSO® as a first-line treatment in certain non-small cell lung cancer patients whose tumors harbor EGFR mutation and overexpress MET.

[Modern Pathology] In this study, 64 surgically resected specimens of paired primary tumors and metastatic tumors were obtained from 28 patients with non-small cell lung cancer. Multiplex immunofluorescence was performed on whole sections.

[Thoracic Cancer] The effect of As4S4 and cisplatin on cell proliferation and apoptosis was investigated in non-small cell lung cancer cell lines. The expression of p53 and PD-L1 proteins was measured by western blotting analysis.

[Journal of Experimental & Clinical Cancer Research] Scientists investigated the role of cold-inducible RNA binding protein (CIRP) in the progression of non-small cell lung cancer (NSCLC) using patient tissue samples, cultured cell lines and animal lung cancer models.

[Molecular Oncology] Co-detection and comprehensive phenotypic and karyotypic molecular characterization of aneuploid circulating tumor cells and circulating tumor endothelial cells were conducted on non-small cell lung cancer patients receiving bevacizumab plus chemotherapy.

[Acta Biochimica et Biophysica Sinica] Researchers investigated the relationship between miR-144-3p and CEP55 expression. They evaluated the association between miR-144-3p and CEP55 expression and proliferation, invasion and apoptosis of non-small cell lung cancer cells.